Tactile Systems Technology logo
Tactile Systems Technology TCMD
$ 21.73 0.09%
report update icon

Quarterly report 2026-Q2
added 08-10-2026

Tactile Systems Technology Income Statement 2025-2011 | TCMD

Brief overview of revenue and earnings at Tactile Systems Technology

This overview is based on financial performance over the past five years. The revenue attributed to Tactile Systems Technology moved from 187 million dollars to 330 million dollars between the two endpoints. The five-year change reached +76.1%, while CAGR stood at 12%. The pace indicates confident and sustained business growth.

At the gross-profit level, the result moved from $133 million to $250 million, a change of +88.3%. Cost of revenue developed more favorably than sales, supporting gross profitability. Comparing the endpoints gives gross margins of 71% and 75.9%. The margin shift points to a more favorable sales-and-cost structure.

Over the period, EBITDA shifted from −$834 thousand to $35.9 million, a change of +4407.2%. Operating profitability strengthened faster than the scale of sales. The EBITDA share of revenue changed from −0.4% to 10.9%. Higher profitability strengthens the quality of operating growth.

Across the five years, the net result shifted from −$620 thousand to $19.1 million. The return to profit marks a meaningful recovery in the final result.

Market value was $869 million at the start and $640 million at the end. Investors remain cautious despite better financial results.

Overall conclusion

The figures do not all move in the same direction. Key strengths include net-income growth, improving gross profitability and positive operating leverage. The main areas of concern are declining capitalization. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Tactile Systems Technology

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

640 M 428 M 322 M 270 M 375 M 869 M 1.08 B 1.21 B 561 M 251 M - - - - -

Shares

22.9 M 23.9 M 22.9 M 20.1 M 19.7 M 19.3 M 18.9 M 18.3 M 17.4 M 16.8 M - - - - -

Historical Prices

28 17.9 14.1 13.5 19 44.9 67.5 45.5 29 16.4 - - - - -

Net Income

19.1 M 17 M 28.5 M -17.9 M -11.8 M -620 K 11 M 6.62 M 5.86 M 2.88 M 1.39 M 2.07 M 3.16 M - -

Revenue

330 M 293 M 274 M 247 M 208 M 187 M 189 M 144 M 109 M 84.5 M 62.9 M 47.7 M 37.2 M - -

Cost of Revenue

79.4 M 76.3 M 79.3 M 70.8 M 59.8 M 54.3 M 55.3 M 41.5 M 29 M 22.9 M 16.9 M 12.7 M - - -

Gross Profit

250 M 217 M 195 M 176 M 148 M 133 M 134 M 102 M 80.3 M 61.6 M 46 M 35 M 27.4 M - -

Operating Income

29.3 M 22.2 M 18 M -12.8 M -1.76 M -3.63 M 10.5 M 2.99 M 3.9 M 4.27 M 3.45 M 3.8 M - - -

EBITDA

35.9 M 29 M 24.6 M -6.49 M 1.92 M -834 K 14 M 6.62 M 5.75 M 5.07 M 4.28 M 4.5 M 2.96 M - -

Operating Expenses

221 M 195 M 177 M 189 M 150 M 136 M 124 M 99.3 M 76.4 M 57.3 M 42.5 M 31.2 M 25 M - -

General and Administrative Expenses

88.7 M 71.1 M 62.1 M 60.8 M 56.8 M 51.3 M 39.6 M 33.6 M 26.9 M 19.1 M 13.7 M 10.2 M 8.28 M - -

All numbers in USD currency

Quarterly Income Statement Tactile Systems Technology

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

23.1 M 23.7 M - 22.3 M 23.1 M 23.7 M 23.9 M 24 M 23.9 M 23.7 M 23.6 M 23.5 M 23.4 M 21.3 M 20.3 M 20.1 M 20 M 19.9 M 19.9 M 19.8 M 19.7 M 19.5 M 19.5 M 19.4 M 19.3 M 19.2 M 19.2 M 19 M 18.9 M 18.7 M 18.6 M 18.3 M 18.2 M 18 M 17.8 M 17.6 M 17.2 M 16.9 M 16.8 M 12.3 M 3.41 M 3.29 M 3.22 M 3.15 M 2.81 M - - - - - - - - - - - - - - - - -

Net Income

3.22 M -2.97 M - 8.21 M 3.22 M -2.97 M - 5.16 M 4.3 M -2.21 M - 22.3 M -100 K -1.89 M - -2.28 M -4.64 M -15.6 M - -4.32 M 1.3 M -2.27 M 12.1 M 2.42 M -13.8 M -1.31 M 4.28 M 2.43 M 2.78 M 1.47 M 2.36 M 1.75 M 2.57 M -50 K 2.23 M 1.34 M 3.79 M -1.5 M 2.38 M 492 K 988 K -980 K 289 K 876 K 138 K -1.34 M - - - - - - - - - - - - - - - -

Revenue

78.9 M 61.3 M - 85.8 M 78.9 M 61.3 M - 73.1 M 73.2 M 61.1 M - 69.6 M 68.3 M 58.8 M - 65.3 M 59.6 M 48 M - 52.5 M 51.1 M 42.8 M 59.2 M 49.1 M 35.1 M 43.7 M 57.1 M 49.6 M 45.2 M 37.6 M 46.4 M 36.3 M 34.1 M 26.8 M 34.9 M 28.3 M 26.3 M 19.8 M 28.5 M 22.6 M 19.7 M 13.7 M 21.2 M 16.8 M 14.8 M 10.1 M - - - - - - - - - - - - - - - -

Cost of Revenue

20.1 M 15.9 M - 20.8 M 20.1 M 15.9 M - 18.3 M 19.1 M 17.7 M - 20.2 M 20 M 17.4 M - 18.5 M 16.4 M 14.1 M - 15.5 M 14.9 M 12.5 M - 14.1 M 10.2 M 12.6 M - 14.2 M 13.7 M 11.4 M - 10.1 M 9.61 M 7.31 M - 7.53 M 7.03 M 5.62 M - 6.28 M 5.32 M 3.81 M - 4.47 M 4.4 M - - - - - - - - - - - - - - - - -

Gross Profit

58.8 M 45.3 M - 65 M 58.8 M 45.3 M - 54.8 M 54.1 M 43.4 M - 49.4 M 48.3 M 41.5 M - 46.8 M 43.2 M 33.9 M - 37 M 36.2 M 30.2 M 41.9 M 35 M 24.9 M 31.1 M 41.1 M 35.4 M 31.5 M 26.3 M 32 M 26.2 M 24.5 M 19.5 M 26.1 M 20.8 M 19.2 M 14.2 M 21 M 16.4 M 14.4 M 9.89 M 16.1 M 12.4 M 10.4 M 7.15 M - - - - - - - - - - - - - - - -

Operating Income

4.08 M -4.54 M - 11 M 4.08 M -4.54 M - 6.78 M 5.85 M -2.96 M - 7.99 M 2.06 M -3.81 M - -1.62 M -4.09 M -14.9 M - -1.37 M -76 K -4.08 M 6.99 M 1.79 M -7.96 M -4.45 M 6.05 M 3.2 M 3.05 M -1.8 M 2.14 M 1.37 M 1.31 M -1.83 M 4.93 M 1.26 M 730 K -2.93 M 3.29 M 974 K 1.79 M -1.79 M 3.24 M 1.46 M 228 K -1.48 M - - - - - - - - - - - - - - - -

EBITDA

4.98 M -3.54 M - 11.9 M 4.98 M -2.82 M - 7.68 M 6.85 M -1.33 M - 8.89 M 3.06 M -2.18 M - -620 K -3.09 M -13.4 M - 783 K 24 K -3.43 M 6.99 M 3.9 M -6.51 M -3.72 M 6.05 M 6.01 M 5.03 M -738 K 2.14 M 3.84 M 3 M -1.36 M 4.93 M 2.33 M 1.39 M -2.63 M 3.29 M 1.65 M 2.23 M -1.58 M 3.24 M 2.08 M 639 K -1.48 M - - - - - - - - - - - - - - - -

Operating Expenses

54.7 M 49.9 M - 54 M 54.7 M 49.9 M - 48 M 48.3 M 46.4 M - 41.4 M 46.2 M 45.3 M - 48.4 M 47.3 M 48.8 M - 38.3 M 36.3 M 34.3 M - 33.2 M 32.9 M 35.5 M - 32.2 M 28.5 M 28.1 M - 24.8 M 23.2 M 21.4 M - 19.6 M 18.5 M 17.2 M - 15.4 M 12.6 M 11.7 M - 10.9 M 10.1 M - - - - - - - - - - - - - - - - -

General and Administrative Expenses

22 M 20 M - 21.4 M 22 M 20 M - 18.1 M 16.8 M 16.3 M - 16.4 M 15 M 15.4 M - 16.3 M 14.9 M 16.2 M - 14.5 M 14.1 M 14.2 M - 12.5 M 14.4 M 10.9 M - 9.97 M 8.81 M 9.39 M - 7.96 M 7.47 M 7.37 M - 7.55 M 6.39 M 5.87 M - 5.12 M 3.97 M 3.41 M - 3.6 M 3.2 M - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Tactile Systems Technology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Sintx Technologies Sintx Technologies
SINT
$ 1.74 6.75 % $ 4.83 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 27.87 0.16 % $ 24.2 B britainBritain
Stryker Corporation Stryker Corporation
SYK
$ 276.43 0.68 % $ 106 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.88 0.4 % $ 1.35 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.16 0.94 % $ 51.6 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.79 0.78 % $ 342 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.49 0.03 % $ 765 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.18 6.76 % $ 1.85 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.83 1.05 % $ 39 M usaUSA
Beyond Air Beyond Air
XAIR
$ 3.38 0.93 % $ 28.1 B usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 94.22 0.69 % $ 18.7 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.23 0.71 % $ 600 M israelIsrael
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 6.81 1.32 % $ 206 M canadaCanada
Abbott Laboratories Abbott Laboratories
ABT
$ 105.52 0.03 % $ 184 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 1.81 1.09 % $ 1.22 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 6.19 1.09 % $ 837 M usaUSA
Align Technology Align Technology
ALGN
$ 153.49 0.03 % $ 11.1 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.05 0.33 % $ 125 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.26 0.37 % $ 31.9 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 9.19 1.29 % $ 1.38 B usaUSA
AxoGen AxoGen
AXGN
$ 46.69 2.51 % $ 2.15 B usaUSA
Butterfly Network Butterfly Network
BFLY
$ 7.52 2.17 % $ 1.86 B usaUSA